Indivior Completes Merger with Supernus, Expanding CNS Portfolio
TipRanks (Mon, 2-Nov 9:58 AM ET)
Indivior’s Q3 showed a 59% adjusted EBITDA margin as SUBLOCADE revenue hit a quarterly record
Market Chameleon (Fri, 30-Oct 5:54 AM ET)
Indivior Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
PRNewswire (Wed, 28-Oct 5:44 PM ET)
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
PRNewswire (Thu, 22-Oct 6:09 PM ET)
Indivior to Report Third Quarter 2026 Financial Results
Globe Newswire (Mon, 19-Oct 8:30 AM ET)
Globe Newswire (Wed, 30-Sep 6:42 PM ET)
Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 29-Sep 1:53 PM ET)
ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH
PRNewswire (Mon, 28-Sep 7:22 PM ET)
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals trades on the NASDAQ stock market under the symbol INDV.
As of November 6, 2026, INDV stock price was flat at $28.15 with million shares trading.
INDV has a beta of 0.12, meaning it tends to be less sensitive to market movements. INDV has a correlation of 0.00 to the broad based SPY ETF.
INDV has a market cap of $3.32 billion. This is considered a Mid Cap stock.
Last quarter Indivior Pharmaceuticals reported $356 million in Revenue and $1.32 earnings per share. This beat revenue expectation by $27 million and exceeded earnings estimates by $.24.
In the last 3 years, INDV traded as high as $42.81 and as low as $7.33.
The top ETF exchange traded funds that INDV belongs to (by Net Assets): VTI, VB, VBK, VXF, VTWO.
INDV has outperformed the market in the last year with a price return of +38.6% while the SPY ETF gained +9.6%. INDV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +14.7% and +25.7%, respectively, while the SPY returned -4.2% and -3.8%, respectively.
INDV support price is $27.56 and resistance is $28.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDV shares will trade within this expected range on the day.